Welcome to our dedicated page for Kronos Bio news (Ticker: KRON), a resource for investors and traders seeking the latest updates and insights on Kronos Bio stock.
Kronos Bio, Inc. (KRON) is a clinical-stage biopharmaceutical company pioneering small molecule therapeutics that target deregulated transcription in cancer and autoimmune disorders. This page provides investors and industry observers with essential updates on the company’s progress, including clinical trial milestones, financial disclosures, and strategic partnerships.
Access real-time announcements about KRON’s innovative pipeline candidates, including CDK9 and p300 KAT inhibitors designed to address high-need oncology indications. Our curated news collection offers insights into the company’s proprietary discovery engine and precision medicine approach while maintaining compliance with financial reporting standards.
Key updates cover earnings reports, research collaborations, regulatory developments, and scientific presentations. Bookmark this page for streamlined access to KRON’s latest advancements in transcription factor therapeutics and biopharmaceutical innovation.
Kronos Bio (NASDAQ: KRON) has announced a definitive merger agreement with Concentra Biosciences, where Concentra will acquire Kronos Bio for $0.57 per share in cash plus a non-tradeable contingent value right (CVR). The CVR includes rights to receive: 50% of net proceeds from KB-9558 and KB-7898 dispositions within 2 years post-closing, 100% of proceeds from KB-0742, lanraplenib and entospletinib dispositions pre-closing, and various percentages of cost savings over three years. The tender offer will commence by May 15, 2025, requiring at least majority shareholder approval and $40.0 million minimum cash at closing. Approximately 27% of shareholders, including officers and directors, have already agreed to tender their shares. The merger is expected to close by mid-2025.
Kronos Bio (NASDAQ: KRON) has released its Q4 and full year 2024 financial results. The company reported cash, cash equivalents and investments of $112.4 million as of December 31, 2024.
Key financial metrics for Q4 2024 include:
- R&D expenses of $8.4 million (including $0.7M in stock-based compensation)
- G&A expenses of $4.9 million (including $1.0M in stock-based compensation)
- Impairment charges and restructuring costs of $16.1 million
- Net loss of $25.8 million ($0.43 per share)
For full year 2024:
- R&D expenses totaled $48.7 million
- G&A expenses reached $24.6 million
- Total impairment and restructuring charges of $29.5 million
- Net loss of $86.1 million ($1.43 per share)
Kronos Bio (NASDAQ: KRON) announced significant leadership changes and restructuring. Deborah Knobelman, Ph.D., will succeed Norbert Bischofberger, Ph.D. as President and Interim CEO effective December 3, 2024. Dr. Bischofberger will remain on the Board of Directors and serve as an advisor. The company also disclosed a major workforce reduction of approximately 83% by year-end, aligning with previously announced cost reduction strategies. The company is exploring strategic options, including potential business combinations and divestiture of preclinical assets, to maximize stockholder value.
Kronos Bio (NASDAQ: KRON) presented preclinical data for its p300 KAT inhibitor program at ACR Convergence 2024. The research focused on KB-7898, demonstrating its ability to reduce inflammation through multiple pathways. Key findings showed that KB-7898 modulated proinflammatory signaling and reduced production of disease-related inflammation markers, including IgG, IL-23, and IL-17A. In the Keyhole Limpet Hemocyanin booster, it achieved up to 50% reduction in KLH-IgG production. The compound also significantly decreased inflammation in a collagen-induced arthritis rat model. The company is currently exploring strategic alternatives, including potential partnerships for its p300 KAT inhibitor programs.
Kronos Bio (NASDAQ: KRON) announced the discontinuation of istisociclib development due to unfavorable benefit-risk profile in platinum-resistant ovarian cancer patients. The Board approved exploring strategic alternatives to maximize stockholder value. The company reported $124.9 million in cash and investments as of September 30, 2024, with a Q3 net loss of $14.1 million. Five out of seven enrolled patients experienced neurological events, leading to three discontinuations. The company will implement cost reductions while exploring options for its preclinical assets, including two p300 KAT inhibitor programs: KB-9558 for multiple myeloma and KB-7898 for Sjögren's disease.
Kronos Bio (KRON) will present preclinical data from its p300 KAT inhibitor program for multiple myeloma at the ASH Annual Meeting in San Diego from December 7-10, 2024. The presentation focuses on KB-9558, their p300 KAT inhibitor being studied for multiple myeloma and HPV-driven tumors.
The research demonstrates a strong relationship between transcription factor IRF4 and p300, a protein affecting cancer cell genes. The findings show these components have a preferential protein-protein interaction through a statistically similar network of interactors, unique among tested transcription factors.
The poster presentation, scheduled for December 9, 2024, will be available on Kronos Bio's website under Publications.
Kronos Bio (NASDAQ: KRON) presented preclinical data from its p300 KAT inhibitor program for HPV-driven tumors at the EORTC-NCI-AACR Symposium. The research demonstrates that their p300 KAT inhibitor, KB-9558, effectively suppresses HPV oncogenes E6 and E7, which are critical for tumor growth. The inhibition leads to restoration of p53 and Rb tumor suppressor pathways, potentially offering a new therapeutic approach for HPV-driven cancers. The study showed that HPV integrates into specific genome locations where p300 regulates transcription, creating a vulnerability that can be targeted by KB-9558.
Kronos Bio (Nasdaq: KRON) will present preclinical data on its p300 KAT inhibitor program for HPV-driven tumors at the EORTC-NCI-AACR Symposium in Barcelona, Spain, from October 23-25, 2024. The company's p300 KAT inhibitor, KB-9558, shows promise in targeting HPV-driven cancers by selectively inhibiting viral oncoproteins E6 and E7.
Key findings include:
- HPV-16 virus hijacks the host transcriptional cofactor p300 to drive expression of E6 and E7 oncogenes
- Inhibition of p300 KAT activity downregulates E6 and E7, reactivating the tumor suppressor p53
- KB-9558 demonstrates high selectivity against HPV oncoproteins
The poster presentation, scheduled for October 24, 2024, will showcase these results, potentially offering new targeted therapies for the estimated 38,000 new cases of HPV-driven cancers annually in the United States.
Kronos Bio has announced the selection of KB-7898, a p300 KAT inhibitor, as its first development candidate for autoimmune diseases, specifically targeting Sjögren’s disease. This candidate stems from Kronos Bio's proprietary discovery engine, which decodes complex transcription factor regulatory networks.
Preclinical data for KB-7898 will be presented at ACR Convergence 2024. The data indicate that p300 KAT inhibition can reduce antibody production in B cells and cytokine production in T cells. Kronos Bio plans to initiate IND-enabling studies of KB-7898 in Q4 2024. The company also intends to explore the candidate's utility in other autoimmune diseases in the future.
The preclinical studies showed promising results, including selective downregulation of cytokines and significant decreases in inflammation in animal models. The presentation will be available on Kronos Bio's website on November 14, 2024, and the abstract is available on the American College of Rheumatology’s website.
Kronos Bio (Nasdaq: KRON) will present preclinical data from its p300 KAT inhibitor program for autoimmune indications at ACR Convergence 2024 in Washington, DC. The presentation, scheduled for November 18, 2024, will showcase how p300 KAT inhibition modulates multiple pro-inflammatory signaling pathways in chronic inflammatory diseases.
The company is exploring the utility of a p300 KAT inhibitor for autoimmune indications, given the role of IRF4 and p300 in immune cells. Kronos Bio remains on track to announce a development candidate for autoimmune diseases by the end of 2024.
The data supports the role of p300 in inflammation and demonstrates that p300 KAT inhibition can modulate pro-inflammatory signaling pathways at well-tolerated in vivo exposures. This approach may address a root cause of inflammation in autoimmune diseases.
FAQ
What is the current stock price of Kronos Bio (KRON)?
What is the market cap of Kronos Bio (KRON)?
